SEC Form 10-K filed by 60 Degrees Pharmaceuticals Inc.
Unavailable
Unavailable
Save time and jump to the most important pieces.
SC 13G - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Subject)
SC 13G/A - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Subject)
SC 13G/A - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Subject)
S-1/A - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Filer)
10-K - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Filer)
SCHEDULE 13G/A - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Subject)
4 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Issuer)
4 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Issuer)
4 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Issuer)
FY 2024 net product revenues increased 140% to $607.6 thousand.FY 2024 gross profit increased $443.8 thousand from ($221 thousand) to $222.8 thousand. WASHINGTON, March 28, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW)) (the "Company"), a pharmaceutical company focused on developing new medicines for infectious diseases, reported today their financial results for the 2024 fiscal year, ended December 31, 2024. Financial Highlights for the Fiscal Year Ended December 31, 2024: Net product revenues increased 140% from $253.6 thousand for fiscal year 2023 to $607.6 thousand for fiscal year 2024; the Company credits growth from domestic commercial sales of ARA
WASHINGTON, Feb. 20, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW)) (the "Company"), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today that it will effect a 1-for-5 reverse stock split ("Reverse Stock Split") of its common stock, par value $0.0001 per share ("Common Stock"). The Common Stock will continue to trade on The Nasdaq Capital Market under the existing symbol "SXTP" and will begin trading on a split-adjusted basis when the market opens on February 24, 2025. The new CUSIP number for the Common Stock following the Reverse Stock Split will be 83006G401. The Reverse Stock Split is primarily intended
WASHINGTON, Feb. 11, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW)) ("60 Degrees" or the "Company"), pharmaceutical company today announced that the United States Food and Drug Administration (FDA) does not object to the Company's plan to import KODATEF® (tafenoquine) from Australia as a one-time, preemptive measure against any near-term disruption in the U.S. supply of ARAKODA® (tafenoquine). ARAKODA is an antimalarial indicated for the prophylaxis of malaria in patients aged 18 years and older in the United States (U.S.) It is sold under the brand name KODATEF in Australia, where it is indicated for the prevention of malaria in adults 18 years of age and
ORLANDO, FL / ACCESSWIRE / December 2, 2024 / RedChip Companies aired interviews with VSee Health, Inc. (NASDAQ:VSEE) and 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV on November 30. Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:VSEE: https://www.redchip.com/assets/access/vsee_accessSXTP: https://www.redchip.com/assets/access/sxtp_accessIn an exclusive interview, Imo Aisiku, M.D., co-CEO and Chairman of VSee Health, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to share insight into how VSee Health's differentiated so
ORLANDO, FL / ACCESSWIRE / November 22, 2024 / RedChip Companies will air interviews with 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) and Can-Fite BioPharma Ltd. (NYSE:CANF)(TASE:CANF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, November 23, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:SXTP: https://www.redchip.com/assets/access/sxtp_accessCANF: https://www.redchip.com/assets/access/canf_accessIn an exclusive interview, Geoffrey Dow, CEO and President of 60 Degrees Pharmaceuticals, appears on the RedChip Small Stocks Big Money™ show on
MELBOURNE, Australia, Sept. 01, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited ((ASX: GTG, NASDAQ:GENE, "Company", "GTG")), a global leader in guideline driven genomics-based tests in health, wellness and serious disease is pleased to advise that RedChip Companies will air interviews with Genetic Technologies Limited (NASDAQ:GENE) and 60 Degrees Pharmaceuticals (60P) (NASDAQ:SXTP) on The RedChip Money Report®, a sponsored program on Bloomberg TV, this Saturday, September 2, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S. Access the interviews in their entirety at: • Genetic Technologies (NASDAQ:GENE): https://www.redchip.com/
4 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Issuer)
4 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Issuer)
4 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Issuer)